Advertisement

Neurochemical Research

, Volume 33, Issue 4, pp 652–667 | Cite as

Molecular Genetics of Monoamine Transporters: Relevance to Brain Disorders

  • K. Haddley
  • A. S. Vasiliou
  • F. R. Ali
  • U. M. Paredes
  • V. J. Bubb
  • J. P. Quinn
Original Paper

Abstract

We have demonstrated in both the human serotonin transporter gene (5HTT) and the dopamine transporter gene (DAT1) that specific polymorphic variants termed Variable Number Tandem Repeats (VNTRs), which correlate with predisposition to a number of neurological and psychiatric disorders, act as transcriptional regulatory domains. We have demonstrated that these domains can act as both tissue-specific and stimulus-inducible regulators of gene expression. As such they can act to be mechanistically associated with the progression or initiation of a behavioural disorder by altering the level of transporter mRNA, which in turn regulates the concentration of transporter in specific cells or in response to a challenge; chemical, environmental or physiological. The synergistic actions of such transcriptional domains will modulate gene expression. Our hypothesis is that these VNTR variants are one mechanism by which nurture can modify concentrations of neurotransmitters in a differential manner.

Keywords

Serotonin transporter Dopamine transporter Polymorphisms Affective disorders VNTR 

References

  1. 1.
    Brookes AJ, Prince JA (2005) Genetic association analysis: lessons from the study of Alzheimers disease. Mutat Res 573:152–159PubMedGoogle Scholar
  2. 2.
    Liu W, Gu N, Feng G, Li S, Bai S, Zhang J, Shen T, Xue H, Breen G, St Clair D, He L (1999) Tentative association of the serotonin transporter with schizophrenia and unipolar depression but not with bipolar disorder in Han Chinese. Pharmacogenetics 9:491–495PubMedGoogle Scholar
  3. 3.
    Evans J, Battersby S, Ogilvie AD, Smith CA, Harmar AJ, Nutt DJ, Goodwin GM (1997) Association of short alleles of a VNTR of the serotonin transporter gene with anxiety symptoms in patients presenting after deliberate self harm. Neuropharmacology 36:439–443PubMedGoogle Scholar
  4. 4.
    Baca-Garcia E, Vaquero-Lorenzo C, Diaz-Hernandez M, Rodriguez-Salgado B, Dolengevich-Segal H, Arrojo-Romero M, Botillo-Martin C, Ceverino A, Piqueras JF, Perez-Rodriguez MM, Saiz-Ruiz J (2007) Association between obsessive-compulsive disorder and a variable number of tandem repeats polymorphism in intron 2 of the serotonin transporter gene. Prog Neuropsychopharmacol Biol Psychiatry 31(2):416–420PubMedGoogle Scholar
  5. 5.
    Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, Smith CA (1996) Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347:731–733PubMedGoogle Scholar
  6. 6.
    Battersby S, Ogilvie AD, Smith CA, Blackwood DH, Muir WJ, Quinn JP, Fink G, Goodwin GM, Harmar AJ (1996) Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet 6:177–181PubMedGoogle Scholar
  7. 7.
    Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, Aitchison KJ, Sodhi M, Li T, Roberts GW, Smith B, Morton J, Murray RM, Smith D, Kirov G (1996) The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 7:1675–1679PubMedGoogle Scholar
  8. 8.
    Bellivier F, Leroux M, Henry C, Rayah F, Rouillon F, Laplanche JL, Leboyer M (2002) Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neurosci Lett 334:17–20PubMedGoogle Scholar
  9. 9.
    Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J (1998) Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia 18:23–26PubMedGoogle Scholar
  10. 10.
    Yilmaz M, Erdal ME, Herken H, Cataloluk O, Barlas O, Bayazit YA (2001) Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci 186:27–30PubMedGoogle Scholar
  11. 11.
    Skipper L, Liu JJ, Tan EK (2006) Polymorphisms in candidate genes: implications for the current treatment of Parkinson’s disease. Expert Opin Pharmacother 7:849–855PubMedGoogle Scholar
  12. 12.
    Fiskerstrand CE, Lovejoy EA, Quinn JP (1999) An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458:171–174PubMedGoogle Scholar
  13. 13.
    MacKenzie A, Quinn J (1999) A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 96:15251–15255PubMedGoogle Scholar
  14. 14.
    Lovejoy EA, Scott AC, Fiskerstrand CE, Bubb VJ, Quinn JP (2003) The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur J Neurosci 17:417–420PubMedGoogle Scholar
  15. 15.
    Klenova E, Scott AC, Roberts J, Shamsuddin S, Lovejoy EA, Bergmann S, Bubb VJ, Royer HD, Quinn JP (2004) YB-1 and CTCF differentially regulate the 5-HTT polymorphic intron 2 enhancer which predisposes to a variety of neurological disorders. J Neurosci 24:5966–5973PubMedGoogle Scholar
  16. 16.
    Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, Craig I, O’Gara C, Bubb VJ, Greenwood T, Kelsoe J, Asherson P, Murray RM, Castelo A, Quinn JP, Vallada H, Breen G (2006) A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 103:4552–4557PubMedGoogle Scholar
  17. 17.
    Quinn JP, Holbrook N, Levens D (1987) Binding of a cellular protein to the gibbon ape leukemia virus enhancer. Mol Cell Biol 7:2735–2744PubMedGoogle Scholar
  18. 18.
    Quinn JP, McGregor RA, Fiskerstrand CE, Davey C, Allan J, Dalziel RG (1998) Identification of a novel multifunctional structural domain in the herpes simplex virus type 1 genome: implications for virus latency. J Gen Virol 79(Pt 10):2529–2532PubMedGoogle Scholar
  19. 19.
    Quinn JP, Takimoto M, Iadarola M, Holbrook N, Levens D (1989) Distinct factors bind the AP-1 consensus sites in gibbon ape leukemia virus and simian virus 40 enhancers. J Virol 63:1737–1742PubMedGoogle Scholar
  20. 20.
    Lesch KP, Meyer J, Glatz K, Flugge G, Hinney A, Hebebrand J, Klauck SM, Poustka A, Poustka F, Bengel D, Mossner R, Riederer P, Heils A (1997) The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm 104:1259–1266PubMedGoogle Scholar
  21. 21.
    Soeby K, Larsen SA, Olsen L, Rasmussen HB, Werge T (2005) Serotonin transporter: evolution and impact of polymorphic transcriptional regulation. Am J Med Genet B Neuropsychiatr Genet 136:53–57PubMedGoogle Scholar
  22. 22.
    Roberts JC, Scott AM, Howard MR, Breen G, Bubb VJ, Klenova E, Quinn JP (2007) Differential regulation of the serotonin transporter gene by lithium is mediated by transcription factors, CCTC binding protein and Y-box binding protein 1, through the polymorphic intron 2 variable number tandem repeat. J Neurosci 27(11):2793–2801PubMedGoogle Scholar
  23. 23.
    Zis AP, Goodwin FK (1979) Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. Arch Gen Psychiatry 36:1097–1107PubMedGoogle Scholar
  24. 24.
    Noach EL (1994) Appetite regulation by serotoninergic mechanisms and effects of d-fenfluramine. Neth J Med 45:123–133PubMedGoogle Scholar
  25. 25.
    Garattini S (1995) Biological actions of drugs affecting serotonin and eating. Obes Res 3(Suppl 4):463S–470SPubMedGoogle Scholar
  26. 26.
    Brunelli M, Garcia-Gil M, Mozzachiodi R, Scuri R, Zaccardi ML (1997) Neurobiological principles of learning and memory. Arch Ital Biol 135:15–36PubMedGoogle Scholar
  27. 27.
    Lesch KP, Merschdorf U (2000) Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law 18:581–604PubMedGoogle Scholar
  28. 28.
    Lesch KP, Zeng Y, Reif A, Gutknecht L (2003) Anxiety-related traits in mice with modified genes of the serotonergic pathway. Eur J Pharmacol 480:185–204PubMedGoogle Scholar
  29. 29.
    Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl 1):2–19PubMedGoogle Scholar
  30. 30.
    McLaughlin DP, Little KY, Lopez JF, Watson SJ (1996) Expression of serotonin transporter mRNA in human brainstem raphe nuclei. Neuropsychopharmacology 15:523–529PubMedGoogle Scholar
  31. 31.
    Zhou FC, Sari Y, Zhang JK (2000) Expression of serotonin transporter protein in developing rat brain. Brain Res Dev Brain Res 119:33–45PubMedGoogle Scholar
  32. 32.
    Blakely RD, Berson HE, Fremeau RT Jr, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354:66–70PubMedGoogle Scholar
  33. 33.
    Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249–263PubMedGoogle Scholar
  34. 34.
    Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288–295PubMedGoogle Scholar
  35. 35.
    Owens MJ, Nemeroff CB (1998) The serotonin transporter and depression. Depress Anxiety 8(Suppl 1):5–12PubMedGoogle Scholar
  36. 36.
    Roman DL, Walline CC, Rodriguez GJ, Barker EL (2003) Interactions of antidepressants with the serotonin transporter: a contemporary molecular analysis. Eur J Pharmacol 479:53–63PubMedGoogle Scholar
  37. 37.
    McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30:1741–1750PubMedGoogle Scholar
  38. 38.
    Mlinar B, Corradetti R (2003) Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur J Neurosci 18:1559–1571PubMedGoogle Scholar
  39. 39.
    Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD (1993) Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90:2542–2546PubMedGoogle Scholar
  40. 40.
    Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR, DelProposto ZS, Hill E, Cassin BJ, Watson SJ, Cook EH (1998) Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 155:207–213PubMedGoogle Scholar
  41. 41.
    Sandhu SK, Ross LS, Gill SS (2002) A cocaine insensitive chimeric insect serotonin transporter reveals domains critical for cocaine interaction. Eur J Biochem 269:3934–3944PubMedGoogle Scholar
  42. 42.
    Lesch KP, Wolozin BL, Estler HC, Murphy DL, Riederer P (1993) Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect 91:67–72PubMedGoogle Scholar
  43. 43.
    Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993) Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60:2319–2322PubMedGoogle Scholar
  44. 44.
    Heils A, Teufel A, Petri S, Seemann M, Bengel D, Balling U, Riederer P, Lesch KP (1995) Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect 102:247–254PubMedGoogle Scholar
  45. 45.
    Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621–2624PubMedCrossRefGoogle Scholar
  46. 46.
    Nakamura M, Ueno S, Sano A, Tanabe H (2000) The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 5:32–38PubMedGoogle Scholar
  47. 47.
    Hu X, Schrodi SJ, Ross DA, Cargill M (2004) Selecting tagging SNPs for association studies using power calculations from genotype data. Hum Hered 57:156–170PubMedGoogle Scholar
  48. 48.
    Kraft JB, Slager SL, McGrath PJ, Hamilton SP (2005) Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58:374–381PubMedGoogle Scholar
  49. 49.
    Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL (2006) Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11:224–226PubMedGoogle Scholar
  50. 50.
    Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH (2004) Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 9:433–441PubMedGoogle Scholar
  51. 51.
    Cervilla JA, Rivera M, Molina E, Torres-Gonzalez F, Bellon JA, Moreno B, de Dios Luna J, Lorente JA, de Diego-Otero Y, King M, Nazareth I, Gutierrez B (2006) The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am J Med Genet B Neuropsychiatr Genet 141:912–917PubMedGoogle Scholar
  52. 52.
    Cho HJ, Meira-Lima I, Cordeiro Q, Michelon L, Sham P, Vallada H, Collier DA (2005) Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. Mol Psychiatry 10:771–781PubMedGoogle Scholar
  53. 53.
    Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531PubMedGoogle Scholar
  54. 54.
    Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science 297:400–403PubMedGoogle Scholar
  55. 55.
    Gerra G, Garofano L, Pellegrini C, Bosari S, Zaimovic A, Moi G, Avanzini P, Talarico E, Gardini F, Donnini C (2005) Allelic association of a dopamine transporter gene polymorphism with antisocial behaviour in heroin-dependent patients. Addict Biol 10:275–281PubMedGoogle Scholar
  56. 56.
    Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389PubMedGoogle Scholar
  57. 57.
    Zalsman G, Huang YY, Oquendo MA, Burke AK, Hu XZ, Brent DA, Ellis SP, Goldman D, Mann JJ (2006) Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 163:1588–1593PubMedGoogle Scholar
  58. 58.
    Hariri AR, Brown SM (2006) Serotonin. Am J Psychiatry 163:12PubMedGoogle Scholar
  59. 59.
    Bengel D, Greenberg BD, Cora-Locatelli G, Altemus M, Heils A, Li Q, Murphy DL (1999) Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. Mol Psychiatry 4:463–466PubMedGoogle Scholar
  60. 60.
    Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D (1998) A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry 3:328–332PubMedGoogle Scholar
  61. 61.
    Sakai K, Nakamura M, Ueno S, Sano A, Sakai N, Shirai Y, Saito N (2002) The silencer activity of the novel human serotonin transporter linked polymorphic regions. Neurosci Lett 327:13–16PubMedGoogle Scholar
  62. 62.
    Mortensen OV, Thomassen M, Larsen MB, Whittemore SR, Wiborg O (1999) Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res Mol Brain Res 68:141–148PubMedGoogle Scholar
  63. 63.
    Hranilovic D, Schwab SG, Jernej B, Knapp M, Lerer B, Albus M, Rietschel M, Kanyas K, Borrmann M, Lichtermann D, Maier W, Wildenauer DB (2000) Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings. Mol Psychiatry 5:91–95PubMedGoogle Scholar
  64. 64.
    Bradley SL, Dodelzon K, Sandhu HK, Philibert RA (2005) Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am J Med Genet B Neuropsychiatr Genet 136:58–61PubMedGoogle Scholar
  65. 65.
    Lim JE, Papp A, Pinsonneault J, Sadee W, Saffen D (2006) Allelic expression of serotonin transporter (SERT) mRNA in human pons: lack of correlation with the polymorphism SERTLPR. Mol Psychiatry 11:649–662PubMedGoogle Scholar
  66. 66.
    Heinz A, Goldman D (2000) Genotype effects on neurodegeneration and neuroadaptation in monoaminergic neurotransmitter systems. Neurochem Int 37:425–432PubMedGoogle Scholar
  67. 67.
    Willeit M, Stastny J, Pirker W, Praschak-Rieder N, Neumeister A, Asenbaum S, Tauscher J, Fuchs K, Sieghart W, Hornik K, Aschauer HN, Brucke T, Kasper S (2001) No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 50:8–12PubMedGoogle Scholar
  68. 68.
    Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V (2000) A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 57:729–738PubMedGoogle Scholar
  69. 69.
    Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F, Hirano M, Shinohara M, Kagami M, Okubo Y, Nankai M, Kanba S (2003) No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 48:184–188PubMedGoogle Scholar
  70. 70.
    Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ (2006) Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 163:48–51PubMedGoogle Scholar
  71. 71.
    Fallgatter AJ, Herrmann MJ, Roemmler J, Ehlis AC, Wagener A, Heidrich A, Ortega G, Zeng Y, Lesch KP (2004) Allelic variation of serotonin transporter function modulates the brain electrical response for error processing. Neuropsychopharmacology 29:1506–1511PubMedGoogle Scholar
  72. 72.
    Jennings KA, Loder MK, Sheward WJ, Pei Q, Deacon RM, Benson MA, Olverman HJ, Hastie ND, Harmar AJ, Shen S, Sharp T (2006) Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 26:8955–8964PubMedGoogle Scholar
  73. 73.
    Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, Riederer P (1994) Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 95:157–162PubMedGoogle Scholar
  74. 74.
    Ohara K, Suzuki Y, Ochiai M, Tsukamoto T, Tani K, Ohara K (1999) A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry 23:55–65PubMedGoogle Scholar
  75. 75.
    Kaiser R, Tremblay PB, Schmider J, Henneken M, Dettling M, Muller-Oerlinghausen B, Uebelhack R, Roots I, Brockmoller J (2001) Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 6:179–185PubMedGoogle Scholar
  76. 76.
    Hranilovic D, Stefulj J, Furac I, Kubat M, Balija M, Jernej B (2003) Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphisms in Croatian suicide victims. Biol Psychiatry 54:884–889PubMedGoogle Scholar
  77. 77.
    Jernej B, Stefulj J, Hranilovic D, Balija M, Skavic J, Kubat M (2004) Intronic polymorphism of tryptophan hydroxylase and serotonin transporter: indication for combined effect in predisposition to suicide. J Neural Transm 111:733–738PubMedGoogle Scholar
  78. 78.
    Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES, Easton DF, Rubinsztein DC (1998) Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet 81:58–63PubMedGoogle Scholar
  79. 79.
    Anguelova M, Benkelfat C, Turecki G (2003) A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry 8:646–653PubMedGoogle Scholar
  80. 80.
    Lotrich FE, Pollock BG (2004) Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 14:121–129PubMedGoogle Scholar
  81. 81.
    Whitaker-Azmitia PM (2001) Serotonin and brain development: role in human developmental diseases. Brain Res Bull 56:479–485PubMedGoogle Scholar
  82. 82.
    Gaspar P, Cases O, Maroteaux L (2003) The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4(12):1002–1012PubMedGoogle Scholar
  83. 83.
    Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780–796PubMedGoogle Scholar
  84. 84.
    Lesch KP, Gutknecht L (2005) Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 29:1062–1073PubMedGoogle Scholar
  85. 85.
    Serretti A, Kato M, De Ronchi D, Kinoshita T (2006) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol PsychiatryGoogle Scholar
  86. 86.
    Franken IH, Booij J, van den Brink W (2005) The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol 526:199–206PubMedGoogle Scholar
  87. 87.
    Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27:270–277PubMedGoogle Scholar
  88. 88.
    Haile CN, Kosten TR, Kosten TA (2007) Genetics of dopamine and its contribution to cocaine addiction. Behav Genet 37:119–145PubMedGoogle Scholar
  89. 89.
    Dani JA (2003) Roles of dopamine signaling in nicotine addiction. Mol Psychiatry 8:255–256PubMedGoogle Scholar
  90. 90.
    Nirenberg MJ, Waters C (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21:524–529PubMedGoogle Scholar
  91. 91.
    Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, Grosset DG (2006) Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21:2206–2208PubMedGoogle Scholar
  92. 92.
    Otmakhova NA, Lisman JE (1996) D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses. J Neurosci 16:7478–7486PubMedGoogle Scholar
  93. 93.
    Swanson-Park JL, Coussens CM, Mason-Parker SE, Raymond CR, Hargreaves EL, Dragunow M, Cohen AS, Abraham WC (1999) A double dissociation within the hippocampus of dopamine D1/D5 receptor and beta-adrenergic receptor contributions to the persistence of long-term potentiation. Neuroscience 92:485–497PubMedGoogle Scholar
  94. 94.
    Li S, Cullen WK, Anwyl R, Rowan MJ (2003) Dopamine-dependent facilitation of LTP induction in hippocampal CA1 by exposure to spatial novelty. Nat Neurosci 6:526–531PubMedGoogle Scholar
  95. 95.
    Swant J, Wagner JJ (2006) Dopamine transporter blockade increases LTP in the CA1 region of the rat hippocampus via activation of the D3 dopamine receptor. Learn Mem 13:161–167PubMedGoogle Scholar
  96. 96.
    Newman J, Grace AA (1999) Binding across time: the selective gating of frontal and hippocampal systems modulating working memory and attentional states. Conscious Cogn 8:196–212PubMedGoogle Scholar
  97. 97.
    Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1–58PubMedGoogle Scholar
  98. 98.
    Sesack SR, Hawrylak VA, Guido MA, Levey AI (1998) Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol 42:171–174PubMedGoogle Scholar
  99. 99.
    Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A (2001) Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 432:119–136PubMedGoogle Scholar
  100. 100.
    Giros B, Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14:43–49PubMedGoogle Scholar
  101. 101.
    Diaz-Asper CM, Weinberger DR, Goldberg TE (2006) Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. NeuroRx 3:97–105PubMedGoogle Scholar
  102. 102.
    Seeman P, Madras BK (1998) Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 3:386–396PubMedGoogle Scholar
  103. 103.
    Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P (2001) The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11:449–455PubMedGoogle Scholar
  104. 104.
    Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104–1106PubMedGoogle Scholar
  105. 105.
    Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kapatos G (1992) Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci USA 89:7095–7099PubMedGoogle Scholar
  106. 106.
    Vandenbergh DJ, Thompson MD, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Zarrabian D, Comings D, Sellers EM, Tyndale RF, George SR, O’Dowd BF, Uhl GR (2000) Human dopamine transporter gene: coding region conservation among normal, Tourette’s disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol Psychiatry 5:283–292PubMedGoogle Scholar
  107. 107.
    Amara SG, Sonders MS, Zahniser NR, Povlock SL, Daniels GM (1998) Molecular physiology and regulation of catecholamine transporters. Adv Pharmacol 42:164–168PubMedGoogle Scholar
  108. 108.
    Sano A, Kondoh K, Kakimoto Y, Kondo I (1993) A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 91:405–406PubMedGoogle Scholar
  109. 109.
    Mitchell RJ, Howlett S, Earl L, White NG, McComb J, Schanfield MS, Briceno I, Papiha SS, Osipova L, Livshits G, Leonard WR, Crawford MH (2000) Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations. Hum Biol 72:295–304PubMedGoogle Scholar
  110. 110.
    Bertolino A, Blasi G, Latorre V, Rubino V, Rampino A, Sinibaldi L, Caforio G, Petruzzella V, Pizzuti A, Scarabino T, Nardini M, Weinberger DR, Dallapiccola B (2006) Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurosci 26:3918–3922PubMedGoogle Scholar
  111. 111.
    Barkley RA, Smith KM, Fischer M, Navia B (2006) An examination of the behavioral and neuropsychological correlates of three ADHD candidate gene polymorphisms (DRD4 7+, DBH TaqI A2, and DAT1 40 bp VNTR) in hyperactive and normal children followed to adulthood. Am J Med Genet B Neuropsychiatr Genet 141:487–498PubMedGoogle Scholar
  112. 112.
    Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993–998PubMedGoogle Scholar
  113. 113.
    Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M (1997) Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 2:311–313PubMedGoogle Scholar
  114. 114.
    Daly G, Hawi Z, Fitzgerald M, Gill M (1999) Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 4:192–196PubMedGoogle Scholar
  115. 115.
    Barr CL, Xu C, Kroft J, Feng Y, Wigg K, Zai G, Tannock R, Schachar R, Malone M, Roberts W, Nothen MM, Grunhage F, Vandenbergh DJ, Uhl G, Sunohara G, King N, Kennedy JL (2001) Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder. Biol Psychiatry 49:333–339PubMedGoogle Scholar
  116. 116.
    Curran S, Mill J, Tahir E, Kent L, Richards S, Gould A, Huckett L, Sharp J, Batten C, Fernando S, Ozbay F, Yazgan Y, Simonoff E, Thompson M, Taylor E, Asherson P (2001) Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry 6:425–428PubMedGoogle Scholar
  117. 117.
    Chen CK, Chen SL, Mill J, Huang YS, Lin SK, Curran S, Purcell S, Sham P, Asherson P (2003) The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol Psychiatry 8:393–396PubMedGoogle Scholar
  118. 118.
    Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M, Posner M (2000) Dopamine genes and ADHD. Neurosci Biobehav Rev 24:21–25PubMedGoogle Scholar
  119. 119.
    Holmes J, Payton A, Barrett JH, Hever T, Fitzpatrick H, Trumper AL, Harrington R, McGuffin P, Owen M, Ollier W, Worthington J, Thapar A (2000) A family-based and case–control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol Psychiatry 5:523–530PubMedGoogle Scholar
  120. 120.
    Feng Y, Wigg KG, Makkar R, Ickowicz A, Pathare T, Tannock R, Roberts W, Malone M, Kennedy JL, Schachar R, Barr CL (2005) Sequence variation in the 3′-untranslated region of the dopamine transporter gene and attention-deficit hyperactivity disorder (ADHD). Am J Med Genet B Neuropsychiatr Genet 139:1–6PubMedGoogle Scholar
  121. 121.
    Cheuk DK, Li SY, Wong V (2006) No association between VNTR polymorphisms of dopamine transporter gene and attention deficit hyperactivity disorder in Chinese children. Am J Med Genet B Neuropsychiatr Genet 141:123–125PubMedGoogle Scholar
  122. 122.
    Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612PubMedGoogle Scholar
  123. 123.
    Carrasco X, Rothhammer P, Moraga M, Henriquez H, Chakraborty R, Aboitiz F, Rothhammer F (2006) Genotypic interaction between DRD4 and DAT1 loci is a high risk factor for attention-deficit/hyperactivity disorder in Chilean families. Am J Med Genet B Neuropsychiatr Genet 141:51–54PubMedGoogle Scholar
  124. 124.
    Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, Sirota LA, Marcus SE, Greenberg BD, Lucas FR 4th, Benjamin J, Murphy DL, Hamer DH (1999) A genetic association for cigarette smoking behavior. Health Psychol 18:7–13PubMedGoogle Scholar
  125. 125.
    Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR, Shields PG (1999) Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18:14–20PubMedGoogle Scholar
  126. 126.
    Timberlake DS, Haberstick BC, Lessem JM, Smolen A, Ehringer M, Hewitt JK, Hopfer C (2006) An association between the DAT1 polymorphism and smoking behavior in young adults from the National Longitudinal Study of Adolescent Health. Health Psychol 25:190–197PubMedGoogle Scholar
  127. 127.
    Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S, Zamora-Paja E, Farahi J, Saxena S, London ED, McCracken JT (2006) Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63:808–816PubMedGoogle Scholar
  128. 128.
    Le Couteur DG, Leighton PW, McCann SJ, Pond S (1997) Association of a polymorphism in the dopamine-transporter gene with Parkinson’s disease. Mov Disord 12:760–763PubMedGoogle Scholar
  129. 129.
    Kim JW, Kim DH, Kim SH, Cha JK (2000) Association of the dopamine transporter gene with Parkinson’s disease in Korean patients. J Korean Med Sci 15:449–451PubMedGoogle Scholar
  130. 130.
    Lim MH, Kim HW, Paik KC, Cho SC, Yoon DY, Lee HJ (2006) Association of the DAT1 polymorphism with attention deficit hyperactivity disorder (ADHD): a family-based approach. Am J Med Genet B Neuropsychiatr Genet 141:309–311PubMedGoogle Scholar
  131. 131.
    Mercier G, Turpin JC, Lucotte G (1999) Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson’s disease: no association found. J Neurol 246:45–47PubMedGoogle Scholar
  132. 132.
    Kelada SN, Costa-Mallen P, Checkoway H, Carlson CS, Weller TS, Swanson PD, Franklin GM, Longstreth WT Jr, Afsharinejad Z, Costa LG (2005) Dopamine transporter (SLC6A3) 5′ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson’s disease. Pharmacogenet Genomics 15:659–668PubMedCrossRefGoogle Scholar
  133. 133.
    Leighton PW, Le Couteur DG, Pang CC, McCann SJ, Chan D, Law LK, Kay R, Pond SM, Woo J (1997) The dopamine transporter gene and Parkinson’s disease in a Chinese population. Neurology 49:1577–1579PubMedGoogle Scholar
  134. 134.
    Sander T, Harms H, Podschus J, Finckh U, Nickel B, Rolfs A, Rommelspacher H, Schmidt LG (1997) Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Biol Psychiatry 41:299–304PubMedGoogle Scholar
  135. 135.
    Schmidt LG, Harms H, Kuhn S, Rommelspacher H, Sander T (1998) Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene. Am J Psychiatry 155(4):474–478PubMedGoogle Scholar
  136. 136.
    Ueno S, Nakamura M, Mikami M, Kondoh K, Ishiguro H, Arinami T, Komiyama T, Mitsushio H, Sano A, Tanabe H (1999) Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism. Mol Psychiatry 4:552–557PubMedGoogle Scholar
  137. 137.
    Need AC, Ahmadi KR, Spector TD, Goldstein DB (2006) Obesity is associated with genetic variants that alter dopamine availability. Ann Hum Genet 70:293–303PubMedGoogle Scholar
  138. 138.
    Yoon DY, Rippel CA, Kobets AJ, Morris CM, Lee JE, Williams PN, Bridges DD, Vandenbergh DJ, Shugart YY, Singer HS (2006) Dopaminergic polymorphisms in Tourette syndrome: association with the DAT gene (SLC6A3). Am J Med Genet B Neuropsychiatr GenetGoogle Scholar
  139. 139.
    Kim SJ, Kim YS, Kim CH, Lee HS (2006) Lack of association between polymorphisms of the dopamine receptor D4 and dopamine transporter genes and personality traits in a Korean population. Yonsei Med J 47:787–792PubMedCrossRefGoogle Scholar
  140. 140.
    Gelernter J, Kranzler HR, Satel SL, Rao PA (1994) Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 11:195–200PubMedGoogle Scholar
  141. 141.
    Byerley W, Hoff M, Holik J, Caron MG, Giros B (1993) VNTR polymorphism for the human dopamine transporter gene (DAT1). Hum Mol Genet 2:335PubMedGoogle Scholar
  142. 142.
    Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP (2001) The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 79:1033–1038PubMedGoogle Scholar
  143. 143.
    Inoue-Murayama M, Adachi S, Mishima N, Mitani H, Takenaka O, Terao K, Hayasaka I, Ito S, Murayama Y (2002) Variation of variable number of tandem repeat sequences in the 3′-untranslated region of primate dopamine transporter genes that affects reporter gene expression. Neurosci Lett 334:206–210PubMedGoogle Scholar
  144. 144.
    Miller GM, Madras BK (2002) Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 7:44–55PubMedGoogle Scholar
  145. 145.
    Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001) The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152–156PubMedGoogle Scholar
  146. 146.
    Mill J, Asherson P, Craig I, D’Souza UM (2005) Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 6:3PubMedGoogle Scholar
  147. 147.
    Mill J, Asherson P, Browes C, D’Souza U, Craig I (2002) Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114:975–979PubMedGoogle Scholar
  148. 148.
    VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6:55PubMedGoogle Scholar
  149. 149.
    Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR (2000) Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133–139PubMedGoogle Scholar
  150. 150.
    Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J (2000) Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157:1700–1703PubMedGoogle Scholar
  151. 151.
    van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46:745–751PubMedGoogle Scholar
  152. 152.
    Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB, Laruelle M (2001) The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24:553–560PubMedGoogle Scholar
  153. 153.
    Lynch DR, Mozley PD, Sokol S, Maas NM, Balcer LJ, Siderowf AD (2003) Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson’s disease. Mov Disord 18:804–812PubMedGoogle Scholar
  154. 154.
    Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, Dondi M, Fanti S, Pettinato C, Baruzzi A (2004) Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin Neuropharmacol 27:111–115PubMedGoogle Scholar
  155. 155.
    Brookes KJ, Mill J, Guindalini C, Curran S, Xu X, Knight J, Chen CK, Huang YS, Sethna V, Taylor E, Chen W, Breen G, Asherson P (2006) A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry 63:74–81PubMedGoogle Scholar
  156. 156.
    O’Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G, Ball D (2007) Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 17:61–67PubMedCrossRefGoogle Scholar
  157. 157.
    Loo SK, Specter E, Smolen A, Hopfer C, Teale PD, Reite ML (2003) Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J Am Acad Child Adolesc Psychiatry 42(8):986–993PubMedGoogle Scholar
  158. 158.
    Winsberg BG, Comings DE (1999) Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474–1477PubMedGoogle Scholar
  159. 159.
    Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH (2005) Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30:1374–1382PubMedGoogle Scholar
  160. 160.
    Joober R, Grizenko N, Sengupta S, Amor LB, Schmitz N, Schwartz G, Karama S, Lageix P, Fathalli F, Torkaman-Zehi A, Stepanian MT (2006) Dopamine transporter 3′-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. NeuropsychopharmacologyGoogle Scholar
  161. 161.
    Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Muller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1:453–460PubMedGoogle Scholar
  162. 162.
    Vostrov AA, Quitschke WW (1997) The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem 272:33353–33359PubMedGoogle Scholar
  163. 163.
    Quitschke WW, Taheny MJ, Fochtmann LJ, Vostrov AA (2000) Differential effect of zinc finger deletions on the binding of CTCF to the promoter of the amyloid precursor protein gene. Nucleic Acids Res 28:3370–3378PubMedGoogle Scholar
  164. 164.
    Ohlsson R, Renkawitz R, Lobanenkov V (2001) CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17:520–527PubMedGoogle Scholar
  165. 165.
    Docquier F, Farrar D, D’Arcy V, Chernukhin I, Robinson AF, Loukinov D, Vatolin S, Pack S, Mackay A, Harris RA, Dorricott H, O’Hare MJ, Lobanenkov V, Klenova E (2005) Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 65:5112–5122PubMedGoogle Scholar
  166. 166.
    Quinn JP (1996) Neuronal-specific gene expression—the interaction of both positive and negative transcriptional regulators. Prog Neurobiol 50:363–379PubMedGoogle Scholar
  167. 167.
    Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, Anney R, Franke B, Gill M, Ebstein R, Buitelaar J, Sham P, Campbell D, Knight J, Andreou P, Altink M, Arnold R, Boer F, Buschgens C, Butler L, Christiansen H, Feldman L, Fleischman K, Fliers E, Howe-Forbes R, Goldfarb A, Heise A, Gabriels I, Korn-Lubetzki I, Johansson L, Marco R, Medad S, Minderaa R, Mulas F, Muller U, Mulligan A, Rabin K, Rommelse N, Sethna V, Sorohan J, Uebel H, Psychogiou L, Weeks A, Barrett R, Craig I, Banaschewski T, Sonuga-Barke E, Eisenberg J, Kuntsi J, Manor I, McGuffin P, Miranda A, Oades RD, Plomin R, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Thompson M, Faraone SV, Asherson P (2006) The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11:934–953PubMedGoogle Scholar
  168. 168.
    Hranilovic D, Stefulj J, Schwab S, Borrmann-Hassenbach M, Albus M, Jernej B, Wildenauer D (2004) Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 55:1090–1094PubMedGoogle Scholar
  169. 169.
    Magi R, Kaplinski L, Remm M (2006) The whole genome tagSNP selection and transferability among HapMap populations. Pac Symp Biocomput 11:535–543Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • K. Haddley
    • 1
  • A. S. Vasiliou
    • 1
  • F. R. Ali
    • 1
  • U. M. Paredes
    • 2
  • V. J. Bubb
    • 1
    • 2
  • J. P. Quinn
    • 1
    • 2
  1. 1.Physiology Laboratory, School of Biomedical ScienceUniversity of LiverpoolLiverpoolEngland
  2. 2.Department of Human Anatomy & Cell Biology, School of Biomedical ScienceUniversity of LiverpoolLiverpoolEngland

Personalised recommendations